Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation

Ryotaro Nakamura(City Of Hope National Medical Center), Anthony S. Stein(University of Hohenheim), Stephen J. Forman(City Of Hope National Medical Center), Guido Marcucci(City of Hope), David Senitzer(City of Hope), Ketevan Gendzekhadze(City Of Hope National Medical Center), John A. Zaia(City Of Hope National Medical Center), Joycelynne Palmer(City of Hope), Ni‐Chun Tsai(City of Hope), Sally Mokhtari(City of Hope)
Leukemia Research
September 28, 2019
10.1016/j.leukres.2019.106230
Cited by 12

Related Papers

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
|Blood|2000|1.6k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k